Reports Q4 revenue $4.02B, consensus $7M. "We are excited about our maturing portfolio as we start 2023. We now have three potential first-in-class clinical-stage programs which are wholly owned or controlled – darovasertib (PKC) in late Phase 2, IDE397 (MAT2A) in Phase 2 monotherapy expansion, and IDE161 (PARG) in Phase 1 dose escalation. A fourth potential first-in-class program, our Pol Theta Helicase development candidate, is advancing into the clinic with IND submission planned in the second quarter of 2023, and the Werner Helicase development candidate nomination is targeted for this year, both in collaboration with GSK. This diverse pipeline of precision medicine therapeutics is unique among our peers and positions us as a leader in precision medicine oncology," said Yujiro Hata, president and CEO, Ideaya Biosciences.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IDYA:
- IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
- Ideaya Biosciences initiated with an Outperform at RBC Capital
- Capital One more bullish on Ideaya Biosciences after study update
- Ideaya Biosciences price target raised to $26 from $22 at Oppenheimer
- Ideaya Biosciences provides update on darovasertib trials
